EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study

Sam Aiyad Ali iD, Mads Ersbøll, Naja Emborg Vinding iD, Jawad Haider Butt iD, Rasmus Rørth iD, Christian Selmer iD, Lucas Malta Westergaard iD, Ulrik Madvig Mogensen iD, Peter E Weeke iD, Christian Jøns iD, Finn Gustafsson iD, Emil Fosbøl iD und 2 weitere

EP Europace · 2023

DOI: 10.1093/europace/euac217 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift EP Europace, 2023. Verfasst von Sam Aiyad Ali und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Amiodarone, Hypothyroidism, Thyroid Diseases, Heart Failure. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Cardiology, Copenhagen University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Thyroid dysfunction is considered the most frequent complication to amiodarone treatment, but data on its occurrence outside clinical trials are sparse. The present study aimed to examine the incidence of thyroid dysfunction following initiation of amiodarone treatment in a nationwide cohort of patients with and without heart failure (HF). Methods and results In Danish registries, we identified all patients with first-time amiodarone treatment during the period 2000–18, without prior thyroid disease or medication. The primary outcome was a composite of thyroid diagnoses and initiation of thyroid drugs. Outcomes were assessed at 1-year follow-up, and for patients free of events in the first year, in a landmark analysis for the subsequent 5 years. We included 43 724 patients with first-time amiodarone treatment, of whom 16 939 (38%) had HF. At 1-year follow-up, the cumulative incidence and adjusted hazard ratio (HR) of the primary outcome were 5.3% and 1.37 (95% confidence interval 1.25–1.50) in patients with a history of HF and 4.2% in those without HF (reference). In the 1-year landmark analysis, the subsequent 5-year cumulative incidences and adjusted HRs of the primary outcome were 5.3% (reference) in patients with 1-year accumulated dose <27.38 g [corresponding to average daily dose (ADD <75 mg)], 14.0% and HR 2.74 (2.46–3.05) for 27.38–45.63 g (ADD 75–125 mg), 20.0% and HR 4.16 (3.77–4.59) for 45.64–63.88 g (ADD 126–175 mg), and 24.5% and HR 5.30 (4.82–5.90) for >63.88 g (ADD >175 mg).

Conclusion

Among patients who initiated amiodarone treatment, around 5% had thyroid dysfunction at 1-year follow-up, with a slightly higher incidence in those with HF. A dose–response relationship was observed between the 1-year accumulated amiodarone dose and the subsequent 5-year cumulative incidence of thyroid dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneHypothyroidismThyroid DiseasesHeart FailureHumansIncidenceCohort StudiesAnti-Arrhythmia Agents

Stichwörter der Autor:innen

AmiodaroneHeart failureHyperthyroidismHypothyroidism

Substanzen

AmiodaroneAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark.
  • Department of Endocrinology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.

ORCID-Profile: Sam Aiyad Ali, Naja Emborg Vinding, Jawad Haider Butt, Rasmus Rørth, Christian Selmer, Lucas Malta Westergaard, Ulrik Madvig Mogensen, Peter E Weeke, Christian Jøns, Finn Gustafsson, Emil Fosbøl, Lars Køber, Søren Lund Kristensen

Förderung

  • Department of Cardiology
  • Copenhagen University Hospital

Zitieren

APA

Ali, S. A., Ersbøll, M., Vinding, N. E., Butt, J. H., Rørth, R., Selmer, C., Westergaard, L. M., Mogensen, U. M., Weeke, P. E., Jøns, C., Gustafsson, F., Fosbøl, E., Køber, L., & Kristensen, S. L. (2023). Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study. EP Europace. https://doi.org/10.1093/europace/euac217

Vancouver

Ali SA, Ersbøll M, Vinding NE, Butt JH, Rørth R, Selmer C, et al. Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study. EP Europace. 2023. doi:10.1093/europace/euac217

BibTeX
@article{Ali2023,
  author = {Ali, Sam Aiyad and Ersbøll, Mads and Vinding, Naja Emborg and Butt, Jawad Haider and Rørth, Rasmus and Selmer, Christian and Westergaard, Lucas Malta and Mogensen, Ulrik Madvig and Weeke, Peter E and Jøns, Christian and Gustafsson, Finn and Fosbøl, Emil and Køber, Lars and Kristensen, Søren Lund},
  title = {Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study},
  journal = {EP Europace},
  year = {2023},
  doi = {10.1093/europace/euac217}
}
Kostenlos starten →